WO2025261456 - ESTROGEN RECEPTOR PROTEOLYSIS-TARGETING CHIMERA COMPOUND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/261456
Publication Date
26.12.2025
International Application No.
PCT/CN2025/102231
International Filing Date
19.06.2025
Title **
[English]
ESTROGEN RECEPTOR PROTEOLYSIS-TARGETING CHIMERA COMPOUND AND USE THEREOF
[French]
COMPOSÉ CHIMÈRE CIBLANT LA PROTÉOLYSE DU RÉCEPTEUR DES OESTROGÈNES ET SON UTILISATION
[Chinese]
一种雌激素受体蛋白降解靶向嵌合体化合物及其应用
Applicants **
GAN & LEE PHARMACEUTICALS CO., LTD.
Inventors
XU, Fuming
CHEN, Wenmin
ZHOU, Guan
XUE, Wei
DING, Yongzheng
WANG, Yuanli
WANG, Kanghua
Priority Data
202410794445.5
19.06.2024
CN
202410867936.8
01.07.2024
CN
202411053133.5
02.08.2024
CN
202411389841.6
08.10.2024
CN
202411946216.7
27.12.2024
CN
202510268544.4
07.03.2025
CN
202510726053.X
03.06.2025
CN
202411057231.6
02.08.2024
CN
202411119789.2
15.08.2024
CN
202411946736.8
27.12.2024
CN
202510348052.6
24.03.2025
CN
202510533415.3
26.04.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4962 | |
| EPO | Filing, Examination, Granting | 32291 | |
| Japan | Filing, Examination, Granting | 2958 | |
| South Korea | Filing, Examination, Granting | 4226 | |
| USA | Filing, Examination, Granting | 13140 |
Total:
57,577
Contact Us
Abstract[English]
Provided in the present disclosure are a new compound that binds to an estrogen receptor protein, an estrogen receptor proteolysis-targeting chimera compound, and the pharmaceutical use thereof. The compounds provided in the present disclosure can be used as an estrogen receptor degrader in the treatment of estrogen-dependent diseases.[French]
La présente invention concerne un nouveau composé qui se lie à une protéine du récepteur des oestrogènes, un composé chimère ciblant la protéolyse du récepteur des oestrogènes, et son utilisation pharmaceutique. Les composés selon la présente divulgation peuvent être utilisés en tant qu'agent de dégradation du récepteur des oestrogènes dans le traitement de maladies dépendantes des oestrogènes.[Chinese]
本公开提供了一种新型的结合雌激素受体蛋白的化合物，以及雌激素受体蛋白降解靶向嵌合体化合物，及其在医药中的应用。本公开提供的化合物能够作为雌激素受体降解剂用于雌激素依赖性疾病的治疗。